Oculis Holding AG

Oculis Holding AG, a Nasdaq-listed biopharma company, provided an update on its clinical pipeline and financial position. The company reported a strong cash runway extending into the second half of 2029, with no debt and an available CHF100m loan facility. Key clinical programs, Privosegtor and Licaminlimab, are progressing with significant upcoming milestones, including trial initiations and topline results.

Oculis Holding AG announced that Sylvia Cheung, a member of its Executive Committee, purchased ordinary shares of the company. This transaction, dated June 10, 2026, was detailed in an attached notification.

Oculis Holding AG announced an upcoming presentation at Clinical Trials at the Summit 2026, where its CEO will discuss Privosegtor's PIONEER registrational program. Privosegtor, a novel neuroprotective candidate for optic neuritis (ON) and other optic neuropathies, has received Breakthrough Therapy designation from the FDA and PRIME designation from the EMA. The company is advancing its late-stage development, supported by encouraging Phase 2 ACUITY data and key regulatory milestones, aiming to address significant unmet medical needs.

Oculis Holding AG announced the vesting and settlement of Restricted Stock Units (RSUs) for two of its directors, Arshad Khanani and Riad Sherif. These RSUs were previously granted to the directors as part of their compensation. The notifications regarding these managers' transactions were attached to the press release, indicating the event occurred on June 6, 2026.

Oculis Holding AG announced that a member of its Executive Committee and Board of Directors, Riad Sherif, purchased ordinary shares of the company. This transaction was detailed in an attached notification.

Oculis Holding AG announced the randomization of the first patient in its PREDICT-1 genotype-based registrational trial for Licaminlimab in dry eye disease (DED). This trial represents the first genotype-based registrational study in DED, aiming to deliver a precision medicine treatment by targeting a specific TNFR1 genotype. With approximately 10 million diagnosed patients in the U.S. suffering from moderate to severe DED and only 13% experiencing sustained relief from current therapies, Licaminlimab has the potential to address a significant unmet medical need. The trial plans to enroll around 160 patients, with a primary endpoint evaluating global ocular discomfort severity in patients with the specified TNFR1 genotype.

Oculis Holding AG announced the randomization of the first patient in the PREDICT-1 genotype-based registrational trial for Licaminlimab in dry eye disease (DED). This FDA-aligned trial targets a specific TNFR1 genotype, aiming to deliver a first-in-class precision medicine. The study plans to enroll approximately 160 patients, with about two-thirds carrying the specified genotype. If approved, Licaminlimab has the potential to transform DED treatment, addressing a market where only 13% of patients find sustained relief and discontinuation rates are high, leveraging promising Phase 2 results.

Oculis Holding AG announced its management will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9. CEO Dr. Riad Sherif will provide an overview and update on its late-stage portfolio, including Privosegtor, which has received Breakthrough Therapy and PRIME designations for optic neuritis, targeting a $7B+ U.S. market. The presentation will also cover Licaminlimab, a topical treatment for dry eye disease in a registrational trial. Oculis highlighted its strong balance sheet and advanced pipeline, preparing for several pivotal readouts with current funding.

Oculis Holding AG announced that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 eye drops in diabetic macular edema (DME) did not meet the primary endpoint of mean change in best corrected visual acuity (BCVA) at Week 52. While a secondary endpoint showed substantial reduction in retinal thickness, the company will not pursue an FDA regulatory filing for OCS-01 in DME. Oculis plans to reallocate resources to its Privosegtor PIONEER program for optic neuropathies and Licaminlimab PREDICT-1 trial for dry eye disease, supported by a strong financial position with $278 million in cash and a runway into 2H 2029.

Oculis Holding AG announced the vesting and settlement of Restricted Stock Units (RSUs) for director Arshad Khanani. This transaction, dated May 25, 2026, is a routine part of the company's compensation plan for its management.